Tanyu Tongzhi Formula (TYTZF) alleviates CHD symptoms patients by increasing peroxisome proliferator-activated receptor (PPAR)-γ expression or activating AKT/ERK signaling pathway (Ma et al., 2021). Here, AKT1 is linked to coronary artery disorder.